Emily
Editor, Senior Moderator
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7924917/
Hainaut, P., & Boffetta, P. (2021). Editorial: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), COVID-19 and cancer: three research questions casting a long shadow. Current opinion in oncology, 33(2), 146?148. https://doi.org/10.1097/CCO.0000000000000715
The year 2020 will go into history books as the year of the COVID-19 epidemic. From the Wuhan outbreak in late 2019 to a global pandemics by mid-2020, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) virus has infected over 70 million people and has so far killed over 1.7 million people -- with global numbers still increasing. The emergence of this new viruses is an unprecedented challenge to public health, causing a societal crisis that places billions into lockdown and dramatically impacts on jobs and economies. Healthcare systems take the brunt of the assault, having not only to deal with massive influx of COVID-19 patients but also with profound disruption of prevention, diagnosis and treatment services for other diseases including cancer. In this editorial, we reflect on the already known and unknown interactions between COVID-19, its causal agent SARS-CoV2 and cancer, and we identify three major questions for further research aimed at addressing the long-term impact of COVID-19 on cancer morbidity and mortality in coming months and years.
Hainaut, P., & Boffetta, P. (2021). Editorial: Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2), COVID-19 and cancer: three research questions casting a long shadow. Current opinion in oncology, 33(2), 146?148. https://doi.org/10.1097/CCO.0000000000000715
The year 2020 will go into history books as the year of the COVID-19 epidemic. From the Wuhan outbreak in late 2019 to a global pandemics by mid-2020, the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV2) virus has infected over 70 million people and has so far killed over 1.7 million people -- with global numbers still increasing. The emergence of this new viruses is an unprecedented challenge to public health, causing a societal crisis that places billions into lockdown and dramatically impacts on jobs and economies. Healthcare systems take the brunt of the assault, having not only to deal with massive influx of COVID-19 patients but also with profound disruption of prevention, diagnosis and treatment services for other diseases including cancer. In this editorial, we reflect on the already known and unknown interactions between COVID-19, its causal agent SARS-CoV2 and cancer, and we identify three major questions for further research aimed at addressing the long-term impact of COVID-19 on cancer morbidity and mortality in coming months and years.